Search - tctmd.com

Displaying 181 - 200 of 1698

Sort: Relevancy | Date

News Daily News

Statins Effective For Primary Prevention in Old and Very Old

Michael O'Riordan

May 29, 2024

News Conference News EuroPCR 2024

FFR-Derived Metric Can Identify Focal CAD Best Suited to PCI

Caitlin E. Cox

May 20, 2024

News Conference News EuroPCR 2024

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Yael L. Maxwell

May 15, 2024

News Daily News

Atherosclerosis Progression May Share Traits With Tumor Growth

Caitlin E. Cox

May 08, 2024

News Daily News

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Michael O'Riordan

May 06, 2024

News Daily News

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Yael L. Maxwell

May 03, 2024

News Daily News

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

Michael O'Riordan

May 02, 2024

News Opinion CV Team Dispatch

May 2024 Dispatch for the CV Team

L.A. McKeown

May 01, 2024

News Industry News

Concept Medical Announces Enrollment of First Patient in “Magical-ISR” IDE Study in the US

April 19, 2024

News Daily News

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Michael O'Riordan

April 17, 2024

News Conference News ACC 2024

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Michael O'Riordan

April 12, 2024

News Conference News ACC 2024

Need a Statin for Primary Prevention? There’s an App for That

Michael O'Riordan

April 10, 2024

$Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC$

News Conference News ACC 2024

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Michael O'Riordan

April 08, 2024

$Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)$

Presentation ACC 2024

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

Presenter: Rasha K. Al-Lamee

April 08, 2024

News Conference News ACC 2024

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Yael L. Maxwell

April 07, 2024

News Conference News ACC 2024

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Yael L. Maxwell

April 06, 2024

Presentation ACC 2024

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Presenter: Yousuf Razvi

April 06, 2024

News Conference News ACC 2024

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Shelley Wood

April 06, 2024

News Industry News

Concept Medical receives US FDA approval for MagicTouch AVF indication, their fifth US clinical study approval for the MagicTouch portfolio

April 03, 2024

News Opinion CV Team Dispatch

April 2024 Dispatch for the CV Team

L.A. McKeown

April 01, 2024

Advertisement

Statins Effective For Primary Prevention in Old and Very Old

FFR-Derived Metric Can Identify Focal CAD Best Suited to PCI

Stepwise DAPT De-escalation Shows Promise in DCB-Only PCI for ACS

Atherosclerosis Progression May Share Traits With Tumor Growth

TAVI Outcomes Linked to LV Recovery in Patients With Severe Dysfunction

Again and Again, Trials Back Short DAPT Post-PCI in ACS: Practice Slow to Shift

Very Elderly Benefit From High-Intensity Lipid-Lowering After Acute MI

May 2024 Dispatch for the CV Team

Concept Medical Announces Enrollment of First Patient in “Magical-ISR” IDE Study in the US

Lp(a) Linked to Higher ASCVD Risks in Diverse Patient Groups

Triglyceride-Lowering Therapies Provide Favorable Outcomes in Early Testing

Need a Statin for Primary Prevention? There’s an App for That

Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC

Coronary Sinus Reducer for the treatment of refractory angina: a randomised, placebo-controlled trial (ORBITA-COSMIC)

ULTIMATE-DAPT: Another Boost for Solo Ticagrelor 1 Month After ACS PCI

Full AEGIS-II Results: Raising HDL With Apo A-I No Help After Acute MI

Acoramidis May Improve Cardiac Function and Promote Regression in Transthyretin Amyloid Cardiomyopathy: Data From the ATTRibute-CM Cardiac Magnetic Resonance Substudy

Early Empagliflozin Doesn’t Curb HF Hospitalizations, Deaths Post-MI: EMPACT-MI

Concept Medical receives US FDA approval for MagicTouch AVF indication, their fifth US clinical study approval for the MagicTouch portfolio

April 2024 Dispatch for the CV Team

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content